Cadrenal Therapeutics, Inc. Common Stock
CVKDHealthcare|Biotechnology|US
$0.98
-0.02 (-2.00%)
DCF Value
$1.73
Tangible Book / Share
$1.40
Cash / Share
$0.82
Financials
Financial Snapshot
Market Cap
$3.5M
Enterprise Value
$1.1M
Revenue (TTM)
$0.00
Net Income (TTM)
-$11.5M
Cash & Investments
$2.4M
Net Cash
$2.4M
Free Cash Flow (TTM)
-$10.2M
Operating CF (TTM)
-$10.2M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$2.4M
Quarterly Burn
$2.5M
Monthly Burn
$846.9K
Est. Runway
~0.9 quarters
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Cash & Investments | $32.6K | $8.4M | $10.0M | $4.0M | $2.4M | |
| Operating Cash Flow | -$1.3M | -$3.5M | -$7.4M | -$12.6M | -$10.2M | |
| Free Cash Flow | -$1.3M | -$3.5M | -$7.4M | -$12.6M | -$10.2M | |
| Capital Expenditure | -$2.5K | -$3.3K | -$6.5K | -$5.1K | -$1.9K | |
| Financing Cash Flow | $1.4M | $11.9M | $9.0M | $6.6M | $7.0M |
R&D Spending
R&D (TTM)
$2.8M
R&D Intensity
—
R&D Growth vs Prior
-30.9%
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $392.9K | $4.1M | $4.2M | $4.1M | $2.8M | |
| SG&A | $2.3M | $3.5M | $6.8M | $9.4M | $8.8M |
Income Statement
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $1.3K | $0.00 | $0.00 | $0.00 | $956.00 | |
| Gross Profit | -$1.3K | $0.00 | $0.00 | $0.00 | -$956.00 | |
| R&D | $392.9K | $4.1M | $4.2M | $4.1M | $2.8M | |
| SG&A | $2.3M | $3.5M | $6.8M | $9.4M | $8.8M | |
| Operating Income | -$2.7M | -$7.6M | -$11.0M | -$13.5M | -$11.7M | |
| Interest Expense | $107.1K | $17.1K | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$6.7M | -$8.4M | -$10.7M | -$13.2M | -$11.5M | |
| Net Income | -$6.7M | -$8.4M | -$10.7M | -$13.2M | -$11.5M | |
| EPS (Diluted) | -8.66 | -9.63 | -8.73 | -6.64 | -4.90 | |
| EBITDA | -$6.6M | -$8.3M | -$10.6M | -$13.2M | -$11.6M | |
| Shares Out. (M) | 0.78 | 0.87 | 1.22 | 1.99 | 2.91 |
Balance Sheet
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $32.6K | $8.4M | $10.0M | $4.0M | $2.4M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $727.6K | $8.5M | $10.1M | $4.3M | $5.6M | |
| Total Assets | $778.2K | $8.5M | $10.1M | $4.3M | $5.6M | |
| Total Current Liabilities | $1.3M | $826.9K | $2.7M | $1.6M | $1.5M | |
| Long-Term Debt | $553.3K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $6.3M | $826.9K | $2.7M | $1.6M | $1.5M | |
| Stockholders' Equity | -$5.6M | $7.7M | $7.4M | $2.7M | $4.1M | |
| Retained Earnings | -$6.7M | -$15.1M | -$25.7M | -$39.0M | -$44.8M |
Cash Flow Statement
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.3M | -$3.5M | -$7.4M | -$12.6M | -$10.2M | |
| Capital Expenditure | -$2.5K | -$3.3K | -$6.5K | -$5.1K | -$1.9K | |
| Free Cash Flow | -$1.3M | -$3.5M | -$7.4M | -$12.6M | -$10.2M | |
| Investing Cash Flow | -$2.5K | -$3.3K | -$6.5K | -$5.1K | -$412.00 | |
| Financing Cash Flow | $1.4M | $11.9M | $9.0M | $6.6M | $7.0M | |
| Issuance of Stock | $0.00 | $11.9M | $5.1M | $7.2M | $6.3M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | -$291.9K | $0.00 | |
| Net Debt Issuance | $0.00 | -$250.0K | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $1.0M | $710.4K | $1.4M | $1.9M | $1.7M | |
| Net Change in Cash | $32.6K | $8.4M | $1.6M | -$6.0M | -$3.2M |
Dilution Tracker
Shares outstanding grew 157.0% over 5 years — significant dilution
Shares Outstanding
4M
5-Year Share Growth
+157.0%
Stock Issuance (TTM)
$6.3M
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.78 | 0.87 | 1.22 | 1.99 | 2.91 | |
| Change vs Prior % | — | 11.9% | 40.5% | 63.5% | 46.1% | |
| Stock Issuance | $0.00 | $11.9M | $5.1M | $7.2M | $6.3M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | -$291.9K | $0.00 | |
| Stock Based Comp. | $1.0M | $710.4K | $1.4M | $1.9M | $1.7M |
Margins & Profitability
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| ROE % | 121.0% | -108.6% | -143.2% | -483.3% | -406.4% | |
| ROA % | -862.8% | -98.1% | -105.2% | -305.9% | -206.5% | |
| ROIC % | 551.0% | -99.0% | -147.3% | -491.5% | -284.8% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 100.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -182.5% | -43.6% | -22.8% | |
| Net Income | 0.0% | -24.5% | -27.5% | -24.3% | |
| EPS (Diluted) | 0.0% | -11.2% | 9.3% | 23.9% | |
| Operating Cash Flow | 0.0% | -168.6% | -108.4% | -71.3% | |
| Free Cash Flow | 0.0% | -168.3% | -108.4% | -71.1% | |
| R&D Expense | 0.0% | 938.9% | 3.0% | -2.5% | |
| SG&A Expense | 0.0% | 53.8% | 90.3% | 38.5% | |
| Total Assets | 0.0% | 994.8% | 18.8% | -57.3% | |
| Book Value / Share | 0.0% | 223.8% | -31.2% | -77.5% | |
| Debt | 0.0% | -96.7% | -100.0% | 0.0% | |
| Diluted Shares | 0.0% | 11.9% | 40.5% | 63.5% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.70
10Y Low / Med / High1.25 / 2.38 / 4.94
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$1.73
Tangible Book / Share
$1.40
Net Current Assets / Share
$1.15
Graham Net-Net
$1.00
Cash / Share
$0.82
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| P/E Ratio | -7.14 | -1.15 | -1.66 | -1.02 | -0.20 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -8.64 | 1.25 | 2.38 | 4.94 | 0.70 | |
| EV/EBITDA | -7.35 | -0.15 | -0.72 | -0.72 | -0.10 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-15.76
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $6.3M | $16.8M |
| Net Income | -$7.7M | -$5.7M | -$3.7M |
| EPS | $-3.86 | $-3.01 | $-1.85 |
| # Analysts (EPS) | 2 | 2 | 2 |